Browsing Tag
Zepbound
22 posts
Why Eli Lillyâs Zepbound just tightened its grip on the obesity drug market in 2026
Find out how Eli Lilly and Company is strengthening Zepboundâs market dominance with a multi-dose KwikPen and reshaping obesity drug access in 2026.
Lillyâs oral GLP-1 orforglipron sustains weight loss after injectables in pivotal Phase 3 trial
Lillyâs orforglipron helped patients maintain weight loss after injectable GLP-1s in a Phase 3 trial. Find out how this could reshape obesity treatment paths.
Can Novo Nordisk catch upâor will Lilly run away with the metabolic crown?
Explore how Eli Lilly and Company and Novo Nordisk are battling for dominance in the metabolic health market, and what could decide the next phase of the obesity drug race.
Whatâs next after Zepbound? Inside Eli Lilly and Companyâs pipeline beyond GLP-1
Discover which drugs Eli Lilly and Company is betting on after Zepbound, including oral GLP-1 pills and next-generation incretins that could redefine the global obesity treatment market.
Will payers embrace premium weight loss? Inside the reimbursement risks of next-gen GLP-1s
As GLPâ1 weightâloss drugs climb toward blockbuster status, insurers and payers face tough choices on coverage. Can premium weightâloss therapies become mainstream?
Is Eli Lilly the NVIDIA of healthcare? How metabolic drugs became the new AI trade
Discover how Eli Lilly and Company crossed the $1 trillion valuation mark and why its metabolic-health franchise is now being valued like a high-growth tech platformâread more now.
Why Eli Lilly (NYSE: LLY) just joined the $1tn clubâand what it means for obesity drug stocks
Find out how Eli Lillyâs weight-loss drug surge has pushed it past a $1 trillion valuationâand what that means for the industry!
Mangoceuticals lands breakthrough partnership with Eli Lilly and Novo Nordisk to deliver low-cost GLP-1 care
Find out how Mangoceuticalsâ partnership with Eli Lilly and Novo Nordisk could transform affordable access to Zepbound and Wegovy obesity treatments.
Zepbound vs Wegovy: How dosing, dual agonists, and payer dynamics are redrawing market lines
Zepbound and Wegovy are reshaping obesity drug competitionâsee how dosing, dual-agonist design, and payer rules define the next pharma showdown.
Can high-dose GLP-1 therapies reshape obesity careâor are we nearing the biological ceiling?
Are high-dose GLP-1 drugs like Wegovy 7.2mg and Zepbound 15mg unlocking better weight lossâor just more side effects? Hereâs what the latest data suggests.